Circulation, 2011 Long-term oral anticoagulation is indicated for several cardiovascular diseases, including the prevention of cardiac thromboembolism in patients with atrial fibrillation (AF),1 mechanical heart valves,2 and acute myocardial infarction (MI),3 as well as the secondary prevention of venous thromboembolism (VTE).4 For the past 60 years, oral vitamin K ...
Graeme J. Hankey, John W. Eikelboom
openalex +3 more sources
Dabigatran etexilate tetrahydrate [PDF]
Acta Crystallographica Section E, 2012 In the title compound, C34H41N7O5·4H2O (systematic name: ethyl 3-{[2-({4-[(Z)-amino(hexyloxycarbonylimino)methyl]anilino}methyl)-1-methylbenzimidazole-5-carbonyl]pyridin-2-ylamino}propanoate tetrahydrate), the benzene and pyridine rings form ...
Hong-Qiang Liu +4 more
doaj +4 more sources
Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis [PDF]
International Journal of Stroke, 2021 Background The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial.
José M. Ferro +11 more
openalex +2 more sources
Synthesis of potential impurities of dabigatran etexilate [PDF]
Synthetic Communications, 2017 The present work describes the origin, control, and synthesis of two potent impurities of dabigatran etexilate 1, dabigatran dimer 2, and dabigatran n-propyl ester 3 from the commercially available raw materials 2-[(4-cyanophenyl)amino]acetic acid (4) and N-[3-amino-4-(methylamino)benzoyl]-N-2-pyridinyl-β-alanine ethyl ester (5).
U. Rajasekhar Reddy +5 more
openalex +3 more sources
Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation [PDF]
TH Open, 2019 Background Dabigatran etexilate has become widely used for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). Currently, there is limited information in real-world patients relating to dabigatran etexilate exposure and ...
Bryan H. Simpson +3 more
doaj +2 more sources
Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. [PDF]
Eur J Drug Metab Pharmacokinet, 2020 Background and Objective Dabigatran etexilate is a non-vitamin K antagonist oral anticoagulant (NOAC) that is used to prevent stroke and systemic embolism in adults with nonvalvular atrial fibrillation (NVAF) and one or more risk factors. Pharmacokinetic
Duan J +5 more
europepmc +2 more sources
Investigation of Solid-State Hydrate-Anhydrous Phase Transformations of Dabigatran Etexilate Hemi-Edisylate [PDF]
Crystals, 2023 In this study, a dabigatran etexilate edisylate (DBE) was prepared by the reaction crystallization of dabigatran etexilate (DBG) and edisilic acid. According to single crystal X-ray diffraction (SXRD), it was revealed that two DGB were combined with one ...
Jin Feng +6 more
doaj +2 more sources
AAPS OpenObjective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered with cobicistat (
Sandy Van Hemelryck +5 more
doaj +2 more sources
Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. [PDF]
Eur J Pharm Sci, 2023 Sia JEV +6 more
europepmc +2 more sources
Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling. [PDF]
Sci Rep, 2020 Dabigatran etexilate (DABE) is a direct oral anticoagulant (DOAC) and may be combined with ticagrelor, a P2Y 12 inhibitor with antiplatelet effects.
Wang N +6 more
europepmc +2 more sources